Compare BIOX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIOX | RFL |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 61.1M |
| IPO Year | 2019 | 2017 |
| Metric | BIOX | RFL |
|---|---|---|
| Price | $0.53 | $1.50 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.33 | N/A |
| AVG Volume (30 Days) | ★ 497.2K | 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.40 | $1.12 |
| 52 Week High | $5.35 | $3.19 |
| Indicator | BIOX | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 72.54 |
| Support Level | $0.53 | $1.41 |
| Resistance Level | $0.67 | $1.64 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 53.63 | 75.00 |
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.